Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cocrystal Pharma, Inc. (COCP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.7400-0.1000 (-3.52%)
At close: 03:59PM EST
2.7400 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement

Cocrystal Pharma, Inc.

19805 North Creek Parkway
Bothell, WA 98011
United States
786 459 1831
https://www.cocrystalpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger D. Kornberg Ph.D.Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board100kN/A1947
Dr. Sam Lee Ph.D.Co-Founder, Interim Co-CEO & Pres432.5kN/A1960
Mr. James J. Martin CPA, CPA, M.B.A., MBAInterim Co-CEO, CFO & Corp. Sec.432.5kN/A1967
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Corporate Governance

Cocrystal Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement